Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.27), $0.07 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.87 million versus the consensus estimate of $9.28 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.